Top entities: ADMA Biologics, Culper Research, Bleichmar Fonti & Auld LLP, Cantor Fitzgerald, United States — United States District Court for the District of New Jersey.

What category does this event fall under?

Regulatory — classified as securities fraud.

What is the sentiment of coverage?

Aggregate sentiment score: -40 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

What were the key actions taken?

ADMA Biologics induced distributor stock · Culper Research published report · Bleichmar Fonti & Auld LLP filed class action lawsuit ADMA Biologics

Is this event still developing?

This is an active story, last updated Jul 16, 2026. Coverage continues to evolve.

Regulatory securities fraud

ADMA Biologics securities fraud class action

Q: When did this event occur?

First reported Jul 14, 2026; last updated Jul 16, 2026.

Q: What is the market impact?

General. ADMA Biologics' stock price fell approximately 29% over two days following the Culper Research report and subsequent analyst downgrade.

Analysis based on 7 articles · First reported Jul 14, 2026 · Last updated Jul 16, 2026

Sentiment

-40

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

ADMA Biologics' stock price fell approximately 29% over two days following the Culper Research report and subsequent analyst downgrade. The class action lawsuit may result in significant financial penalties and reputational damage for the company, potentially affecting its market valuation and investor confidence.

biopharmaceuticals

Event Summary

A securities fraud class action lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ:ADMA) and certain senior executives by law firm Bleichmar Fonti & Auld LLP LLP. The lawsuit alleges that ADMA engaged in a channel stuffing scheme to inflate revenue growth, reporting 20% growth in 2025 when actual growth was reportedly -3%. The allegations were first raised by Culper Research in a report published on March 24, 2026, causing ADMA's stock to drop 16.6% that day and an additional 15% the next day. Subsequently, Cantor Fitzgerald downgraded ADMA's stock rating, leading to further declines. The case is pending in the U.S. District Court for the District of New Jersey, with a lead plaintiff deadline of August 10, 2026.

Key Actions

100 ADMA Biologics induced distributor stock

90 Culper Research published report

80 Bleichmar Fonti & Auld LLP filed class action lawsuit ADMA Biologics

70 Cantor Fitzgerald downgraded stock rating ADMA Biologics

Entities Involved

stock

ADMA Biologics

ADMA Biologics is the defendant in the securities fraud class action, accused of channel stuffing to inflate revenue. Its stock price dropped sharply, and it faces potential legal liabilities and reputational harm.

Importance 100.0 Sentiment -80.0

priv

Culper Research

Culper Research published the report that triggered the stock drop and subsequent lawsuit, alleging channel stuffing by ADMA.

Importance 50.0 Sentiment 0.0

priv

Bleichmar Fonti & Auld LLP

The law firm filed the class action lawsuit on behalf of investors, seeking to recover losses. The firm's role is as plaintiff counsel.

Importance 30.0 Sentiment 10.0

priv

Cantor Fitzgerald

Cantor Fitzgerald downgraded ADMA's stock rating following the short report, contributing to further stock price decline.

Importance 20.0 Sentiment -10.0

govactor

United States — United States District Court for the District of New Jersey

The court is presiding over the class action lawsuit, which will determine the outcome of the case.

Importance 10.0 Sentiment 0.0

govactor

United States — United States Securities and Exchange Commission

The SEC is referenced as the regulator under whose rules the securities fraud claims are brought, but no direct action by the SEC is reported.

Importance 10.0 Sentiment 0.0

Relationships

ADMA Biologics target ↔ Culper Research ADMA Biologics is the target of an activist short campaign by Culper Research, facing intense scrutiny and subsequent cl

ADMA Biologics related ↔ Bleichmar Fonti & Auld LLP

ADMA Biologics related ↔ Cantor Fitzgerald

ADMA Biologics related ↔ United States — United States District Court for the District of New Jersey

Culper Research related ↔ Bleichmar Fonti & Auld LLP

Culper Research related ↔ Cantor Fitzgerald

Culper Research related ↔ United States — United States District Court for the District of New Jersey

Bleichmar Fonti & Auld LLP related ↔ United States — United States District Court for the District of New Jersey

Bleichmar Fonti & Auld LLP related ↔ United States — United States Securities and Exchange Commission

Cantor Fitzgerald related ↔ United States — United States Securities and Exchange Commission

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard